95 related articles for article (PubMed ID: 18299479)
1. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.
van Boekel G; Ruinemans-Koerts J; Joosten F; Dijkhuizen P; van Sorge A; de Boer H
Eur J Endocrinol; 2008 Mar; 158(3):431-7. PubMed ID: 18299479
[TBL] [Abstract][Full Text] [Related]
2. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.
Takeuchi Y; Suzuki H; Ogura S; Imai R; Yamazaki Y; Yamashita T; Miyamoto Y; Okazaki H; Nakamura K; Nakahara K; Fukumoto S; Fujita T
J Clin Endocrinol Metab; 2004 Aug; 89(8):3979-82. PubMed ID: 15292336
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia.
Then C; Asbach E; Bartsch H; Thon N; Betz C; Reincke M; Schmidmaier R
Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31963334
[TBL] [Abstract][Full Text] [Related]
4. Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23.
Bansal S; Khazim K; Suri R; Martin D; Werner S; Fanti P
Clin Nephrol; 2016 Jan; 85(1):57-62. PubMed ID: 26521888
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
6. Successful Superficial Blood Sampling to Localize a Fibroblast Growth Factor-23-Producing Tumor.
Rikitake J; Ashida K; Nagayama A; Inoguchi Y; Hasuzawa N; Koganemaru M; Hamada T; Moritaka K; Demiya M; Sako T; Akiba J; Hiraoka K; Nomura M
Am J Case Rep; 2024 Apr; 25():e943152. PubMed ID: 38613142
[TBL] [Abstract][Full Text] [Related]
7. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors.
Andreopoulou P; Dumitrescu CE; Kelly MH; Brillante BA; Cutler Peck CM; Wodajo FM; Chang R; Collins MT
J Bone Miner Res; 2011 Jun; 26(6):1295-302. PubMed ID: 21611969
[TBL] [Abstract][Full Text] [Related]
8. Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's lymphoma.
Elderman JH; Wabbijn M; de Jongh F
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27118742
[TBL] [Abstract][Full Text] [Related]
9. Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones: Seventeen Cases with More Than One Year of Follow-up.
Wang H; Zhong D; Liu Y; Jiang Y; Qiu G; Weng X; Xing X; Li M; Meng X; Li F; Zhu Z; Yu W; Xia W; Jin J
J Bone Joint Surg Am; 2015 Jul; 97(13):1084-94. PubMed ID: 26135075
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced osteomalacia: a case of diagnostic dilemma.
Robertson A; Mansberg R; Mansberg V; Van der Wall H; Hooper M
Clin Nucl Med; 2007 Aug; 32(8):631-4. PubMed ID: 17667438
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced osteomalacia originating from the temporal bone: a case report.
Kobayashi K; Nakao K; Kawai K; Ito K; Hukumoto S; Asakage T; Oota S; Motoi R
Head Neck; 2011 Jul; 33(7):1072-5. PubMed ID: 20146335
[TBL] [Abstract][Full Text] [Related]
12. Determination of the elimination half-life of fibroblast growth factor-23.
Khosravi A; Cutler CM; Kelly MH; Chang R; Royal RE; Sherry RM; Wodajo FM; Fedarko NS; Collins MT
J Clin Endocrinol Metab; 2007 Jun; 92(6):2374-7. PubMed ID: 17374707
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.
Mori Y; Ogasawara T; Motoi T; Shimizu Y; Chikazu D; Tamura K; Fukumoto S; Takato T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Mar; 109(3):e57-63. PubMed ID: 20219587
[TBL] [Abstract][Full Text] [Related]
14. Development of tumor-induced osteomalacia in a subcutaneous tumor, defined by venous blood sampling of fibroblast growth factor-23.
Ogura E; Kageyama K; Fukumoto S; Yagihashi N; Fukuda Y; Kikuchi T; Masuda M; Suda T
Intern Med; 2008; 47(7):637-41. PubMed ID: 18379151
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.
Ferrari SL; Bonjour JP; Rizzoli R
J Clin Endocrinol Metab; 2005 Mar; 90(3):1519-24. PubMed ID: 15613425
[TBL] [Abstract][Full Text] [Related]
16. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
17. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
Bai X; Miao D; Li J; Goltzman D; Karaplis AC
Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced osteomalacia: The tumor may stay hidden!
van der Rest C; Cavalier E; Kaux JF; Krzesinski JM; Hustinx R; Reginster JY; Delanaye P
Clin Biochem; 2011 Oct; 44(14-15):1264-6. PubMed ID: 21843522
[TBL] [Abstract][Full Text] [Related]
20. Tumor-induced osteomalacia: lessons learned.
Lewiecki EM; Urig EJ; Williams RC
Arthritis Rheum; 2008 Mar; 58(3):773-7. PubMed ID: 18311810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
